Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events

Journal of Translational Medicine

Rui-Ru Ji¹  Maria Jure-Kunkel¹  Lisa Panting¹  Beihong Hu¹  Zenta Tsuchihashi¹  Lisu Wang¹  Scott D Chasalow¹  David Berman¹  Vafa Shahabi¹ 

[1]Bristol-Myers Squibb Company, Princeton, NJ, USA

关键词: Diarrhea;    GI irAE;    Gene expression;    Biomarkers;    Gene expression profiling;    Adverse events;    Colitis;    Gastrointestinal;    Ipilimumab;    Metastatic melanoma;   

Others  :  827877
DOI  :  10.1186/1479-5876-11-75

 received in 2013-01-27, accepted in 2013-03-08,  发布年份 2013

【 摘 要 】

Background

Treatment with ipilimumab, a fully human anti-CTLA-4 antibody approved for the treatment of advanced melanoma, is associated with some immune-related adverse events (irAEs) such as colitis (gastrointestinal irAE, or GI irAE) and skin rash, which are managed by treatment guidelines. Nevertheless, predictive biomarkers that can help identify patients more likely to develop these irAEs could enhance the management of these toxicities.

Methods

To identify candidate predictive biomarkers associated with GI irAEs, gene expression profiling was performed on whole blood samples from 162 advanced melanoma patients at baseline, 3 and 11 weeks after the start of ipilimumab treatment in two phase II clinical trials (CA184004 and CA184007). Overall, 49 patients developed Grade 2 or higher (grade 2+) GI irAEs during the course of treatment. A repeated measures analysis of variance (ANOVA) was used to evaluate the differences in mean expression levels between the GI irAE and No-GI irAE groups of patients at the three time points.

Results

In baseline samples, 27 probe sets showed differential mean expression (≥ 1.5 fold, P ≤ 0.05) between the GI irAE and No-GI irAE groups. Most of these probe sets belonged to three functional categories: immune system, cell cycle, and intracellular trafficking. Changes in gene expression over time were also characterized. In the GI irAE group, 58 and 247 probe sets had a ≥ 1.5 fold change in expression from baseline to 3 and 11 weeks after first ipilimumab dose, respectively. In particular, on-treatment expression increases of CD177 and CEACAM1, two neutrophil-activation markers, were closely associated with GI irAEs, suggesting a possible role of neutrophils in ipilimumab-associated GI irAEs. In addition, the expression of several immunoglobulin genes increased over time, with greater increases in patients with grade 2+ GI irAEs.

Conclusions

Gene expression profiling of peripheral blood, sampled before or early in the course of treatment with ipilimumab, resulted in the identification of a set of potential biomarkers that were associated with occurrence of GI irAEs. However, because of the low sensitivity of these biomarkers, they cannot be used alone to predict which patients will develop GI irAEs. Further investigation of these biomarkers in a larger patient cohort is warranted.

【 授权许可】

   
2013 Shahabi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Korman AJ, Peggs KS, Allison JP: Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006, 90:297-339.
• [2]Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8):711-723.
• [3]Weber J: Overcoming immunologic tolerance to melanoma: targeting ctla-4 with ipilimumab (mdx-010). Oncologist 2008, 13(Suppl 4):16-25.
• [4]Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M: Enterocolitis in patients with cancer after antibody blockade of cytotoxic t-lymphocyte-associated antigen 4. J Clin Oncol 2006, 24(15):2283-2289.
• [5]Berman D, Parker SM, Siegel J, Chasalow SD, Weber J, Galbraith S, Targan SR, Wang HL: Blockade of cytotoxic t-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 2010, 10:11.
• [6]Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J: A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009, 15(17):5591-5598.
• [7]Minor DR, Chin K, Kashani-Sabet M: Infliximab in the treatment of anti-ctla4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother Radiopharm 2009, 24(3):321-325.
• [8]Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, Gomez H, Bastholt L, Chasalow SD: A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 2011, 9:204. BioMed Central Full Text
• [9]Weber J, Hamid O, Wolchok J, Amin A, Masson E, Goldberg S, Williams D, Parker S, Alaparthy S, O’Day S: Assessment of pharmacokinetic interaction between ipilimumab and chemotherapy in a randomized study. 35th ESMO Congress Abstract 1329P 2010.
• [10]Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-Kunkel M, Siemers NO, Jackson JR: An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2011, 61(7):1019-1031.
• [11]Wang X, Rickert M, Garcia KC: Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. Science 2005, 310(5751):1159-1163.
• [12]Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS, Baum PR, Lin TS, Jarjoura D, Lehman A, Kussewitt D: Targeting cd37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 2007, 110(7):2569-2577.
• [13]Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA: Interleukin-32: A cytokine and inducer of tnfalpha. Immunity 2005, 22(1):131-142.
• [14]Zhang H, Sun C, Glogauer M, Bokoch GM: Human neutrophils coordinate chemotaxis by differential activation of rac1 and rac2. J Immunol 2009, 183(4):2718-2728.
• [15]McMahon LW, Walsh CE, Lambert MW: Human alpha spectrin ii and the fanconi anemia proteins fanca and fancc interact to form a nuclear complex. J Biol Chem 1999, 274(46):32904-32908.
• [16]Segura-Totten M, Wilson KL: Baf: Roles in chromatin, nuclear structure and retrovirus integration. Trends Cell Biol 2004, 14(5):261-266.
• [17]Peelman LJ, Chardon P, Nunes M, Renard C, Geffrotin C, Vaiman M, Van Zeveren A, Coppieters W, van de Weghe A, Bouquet Y: The bat1 gene in the mhc encodes an evolutionarily conserved putative nuclear rna helicase of the dead family. Genomics 1995, 26(2):210-218.
• [18]Gearhart MD, Corcoran CM, Wamstad JA, Bardwell VJ: Polycomb group and scf ubiquitin ligases are found in a novel bcor complex that is recruited to bcl6 targets. Mol Cell Biol 2006, 26(18):6880-6889.
• [19]Lee YS, Chen CH, Chao A, Chen ES, Wei ML, Chen LK, Yang KD, Lin MC, Wang YH, Liu JW, Eng HL: Molecular signature of clinical severity in recovering patients with severe acute respiratory syndrome coronavirus (sars-cov). BMC Genomics 2005. BioMed Central Full Text
• [20]Fujibuchi T, Abe Y, Takeuchi T, Imai Y, Kamei Y, Murase R, Ueda N, Shigemoto K, Yamamoto H, Kito K: Aip1/wdr1 supports mitotic cell rounding. Biochem Biophys Res Commun 2005, 327(1):268-275.
• [21]Tebar F, Bohlander SK, Sorkin A: Clathrin assembly lymphoid myeloid leukemia (calm) protein: Localization in endocytic-coated pits, interactions with clathrin, and the impact of overexpression on clathrin-mediated traffic. Mol Biol Cell 1999, 10(8):2687-2702.
• [22]Bernstein AM, Whiteheart SW: Identification of a cellubrevin/vesicle associated membrane protein 3 homologue in human platelets. Blood 1999, 93(2):571-579.
• [23]Lalezari P, Murphy GB, Allen FH Jr: Nb1, a new neutrophil-specific antigen involved in the pathogenesis of neonatal neutropenia. J Clin Invest 1971, 50(5):1108-1115.
• [24]Stroncek DF, Shankar RA, Noren PA, Herr GP, Clement LT: Analysis of the expression of nb1 antigen using two monoclonal antibodies. Transfusion 1996, 36(2):168-174.
• [25]Stroncek DF, Skubitz KM, McCullough JJ: Biochemical characterization of the neutrophil-specific antigen nb1. Blood 1990, 75(3):744-755.
• [26]Rosenbauer F, Wagner K, Zhang P, Knobeloch KP, Iwama A, Tenen DG: Pdp4, a novel glycoprotein secreted by mature granulocytes, is regulated by transcription factor pu.1. Blood 2004, 103(11):4294-4301.
• [27]Miyauchi J, Watanabe Y: Immunocytochemical localization of lactoferrin in human neutrophils. An ultrastructural and morphometrical study. Cell Tissue Res 1987, 247(2):249-258.
• [28]Falloon J, Gallin JI: Neutrophil granules in health and disease. J Allergy Clin Immunol 1986, 77(5):653-662.
• [29]Gabay JE, Scott RW, Campanelli D, Griffith J, Wilde C, Marra MN, Seeger M, Nathan CF: Antibiotic proteins of human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A 1989, 86(14):5610-5614.
• [30]Korkmaz B, Horwitz MS, Jenne DE, Gauthier F: Neutrophil elastase, proteinase 3, and cathepsin g as therapeutic targets in human diseases. Pharmacol Rev 2010, 62(4):726-759.
• [31]Zhao L, Furebring M, Xu S, Venge P: Subcellular localization and mobilization of carcinoembryonic antigen-related cell adhesion molecule 8 in human neutrophils. Br J Haematol 2004, 125(5):666-673.
• [32]Skubitz KM, Skubitz AP: Interdependency of ceacam-1, -3, -6, and −8 induced human neutrophil adhesion to endothelial cells. J Transl Med 2008, 6:78. BioMed Central Full Text
• [33]Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, Baldwin N, Stichweh D, Blankenship D, Li L, Munagala I, Bennett L: A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 2008, 29(1):150-164.
• [34]Robert C, Thomas L, Bondarenko I, O’Day S, DJ M, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364(26):2517-2526.
• [35]Shioya M, Nishida A, Yagi Y, Ogawa A, Tsujikawa T, Kim-Mitsuyama S, Takayanagi A, Shimizu N, Fujiyama Y, Andoh A: Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. Clin Exp Immunol 2007, 149(3):480-486.
• [36]Cagnard N, Letourneur F, Essabbani A, Devauchelle V, Mistou S, Rapinat A, Decraene C, Fournier C, Chiocchia G: Interleukin-32, ccl2, pf4f1 and gfd10 are the only cytokine/chemokine genes differentially expressed by in vitro cultured rheumatoid and osteoarthritis fibroblast-like synoviocytes. Eur Cytokine Netw 2005, 16(4):289-292.
• [37]Monsurro V, Wang E, Yamano Y, Migueles SA, Panelli MC, Smith K, Nagorsen D, Connors M, Jacobson S, Marincola FM: Quiescent phenotype of tumor-specific cd8+ t cells following immunization. Blood 2004, 104(7):1970-1978.
• [38]Jaeschke H, Smith CW, Clemens MG, Ganey PE, Roth RA: Mechanisms of inflammatory liver injury: adhesion molecules and cytotoxicity of neutrophils. Toxicol Appl Pharmacol 1996, 139(2):213-226.
• [39]Segura RM, Alegre J, Varela E, Marti R, Surinach JM, Jufresa J, Armadans L, Pascual C, Fernandez de Sevilla T: Interleukin-8 and markers of neutrophil degranulation in pleural effusions. Am J Respir Crit Care Med 1998, 157(5 Pt 1):1565-1572.
• [40]Jacobs L, Nawrot TS, de Geus B, Meeusen R, Degraeuwe B, Bernard A, Sughis M, Nemery B, Panis LI: Subclinical responses in healthy cyclists briefly exposed to traffic-related air pollution: an intervention study. Environ Health 2010. Published online 2010 October 25 BioMed Central Full Text
• [41]De Larco JE, Wuertz BR, Furcht LT: The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res 2004, 10(15):4895-4900.
• [42]Waugh DJ, Wilson C: The interleukin-8 pathway in cancer. Clin Cancer Res 2008, 14(21):6735-6741.
• [43]Follin P, Wymann MP, Dewald B, Ceska M, Dahlgren C: Human neutrophil migration into skin chambers is associated with production of nap-1/il8 and c5a. Eur J Haematol 1991, 47(1):71-76.
• [44]Gohring K, Wolff J, Doppl W, Schmidt KL, Fenchel K, Pralle H, Sibelius U, Bux J: Neutrophil cd177 (nb1 gp, hna-2a) expression is increased in severe bacterial infections and polycythaemia vera. Br J Haematol 2004, 126(2):252-254.
• [45]Sachs UJ, Andrei-Selmer CL, Maniar A, Weiss T, Paddock C, Orlova VV, Choi EY, Newman PJ, Preissner KT, Chavakis T, Santoso S: The neutrophil-specific antigen cd177 is a counter-receptor for platelet endothelial cell adhesion molecule-1 (cd31). J Biol Chem 2007, 282(32):23603-23612.
• [46]Gray-Owen SD, Blumberg RS: Ceacam1: contact-dependent control of immunity. Nature Rev 2006, 6(6):433-446.
• [47]Skubitz KM, Skubitz AP: Two new synthetic peptides from the n-domain of ceacam1 (cd66a) stimulate neutrophil adhesion to endothelial cells. Biopolymers 2011, 96(1):25-31.
• [48]Costello CM, Mah N, Hasler R, Rosenstiel P, Waetzig GH, Hahn A, Lu T, Gurbuz Y, Nikolaus S, Albrecht M, Hampe J: Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. PLoS Med 2005, 2(8):e199.
• [49]Witko-Sarsat V, Rieu P, Descamps-Latscha B, Lesavre P, Halbwachs-Mecarelli L: Neutrophils: molecules, functions and pathophysiological aspects. Lab Invest 2000, 80(5):617-653.
• [50]Kabakchiev B, Turner D, Hyams J, Mack D, Leleiko N, Crandall W, Markowitz J, Otley AR, Xu W, Hu P, Griffiths AM: Gene expression changes associated with resistance to intravenous corticosteroid therapy in children with severe ulcerative colitis. PLoS One 2010, 5(9):e13085.
• [51]Merlo A, Tenca C, Fais F, Battini L, Ciccone E, Grossi CE, Saverino D: Inhibitory receptors cd85j, lair-1, and cd152 down-regulate immunoglobulin and cytokine production by human b lymphocytes. Clin Diagn Lab Immunol 2005, 12(6):705-712.